Phosphodiesterase 5 inhibitors

Erectile dysfunction (ED) is a major health problem in the world. The key to drug treatment depends on phosphodiesterase 5 inhibitors (PDE5I). Avanafil, denafil, milronafil, tadalafil, tadalafil, udenafil and vardenafil are the seven common PDE5Is at present, and their efficacy is accurate. However, the best PDE5I for treating ED is still inconclusive at this stage.

The key basis for efficacy evaluation in scientific research is the International Index of Erectile Function (IIEF-EF) > 26, the General Assessment Questionnaire (GAQ-1), the penis insertion rate (SEP2) and the sexual intercourse rate (SEP 3). The side effect evaluation includes all side effects or adverse reactions reported in scientific research. The most common side effects are headache, facial flushing, indigestion and nasal congestion.

In the analysis of the strongly recommended original dosage, it was found that 50 mg of tadalafil had the strongest efficacy, but also had the highest overall adverse reaction rate. 10 mg of tadalafil had a moderate efficacy, but had the lowest adverse reaction rate. When vardenafil 10 mg and avanafil 100 mg were compared with 50 mg of tadalafil, the adverse reaction rates were similar, but the overall effect was significantly less than tadalafil. 100 mg of udenafil had similar efficacy to 10 mg of tadalafil, but the adverse reaction rate of udenafil was higher.

In summary, all PDE5Is in the study are effective relative to placebo. Patients who pursue high efficacy are preferred to take tadalafil 50 mg. Patients who want the best tolerance can choose tadalafil 10 mg, and when the efficacy is not good, they can switch to udenafil 100 mg. Based on this study, clinicians can intuitively understand the efficacy and side effects of various PDE5Is in the treatment of erectile dysfunction, and can also adjust the use of drugs in a timely and accurate manner according to the different needs of patients.